Blackrock Neurotech announced that it has received breakthrough device designation from the FDA for its MoveAgain brain-computer interface (BCI) system.
Salt Lake City-based Blackrock Neurotech designed its MoveAgain BCI system to give immobile patients the ability to control a mouse cursor, keyboard, mobile / tablet device, wheelchair or prosthesis by thinking only, according to a Press release.
The company said the results of its portable MoveAgain BCI could include improved mobility and independence that lead to return to work, participation in leisure activities and more efficient and faster communication.
MoveAgain BCI comprises a network implanted in the brain, which decodes movement from neural activity. The signals are then transmitted wirelessly to an external device, such as a slider or a wheelchair, allowing people to control their outside environment.
“We look forward to working closely with the FDA to prioritize the development of the MoveAgain brain-computer interface system, which will bring us closer to our goal of commercialization in 2022,” said Marcus Gerhardt, co-founder and CEO of Blackrock Neurotech, in the press release. “Quadriplegic patients are eager to access it and we are committed to improving their ability to increase their independence through our BCI technology. “
Blackrock Neurotech president and chairman Florian Solzbacher added that the company believes it has enough safety and efficacy data to support early applications, while large-scale integration technologies have enabled a further miniaturization as the company seeks to develop a wireless version.
Solzbacher noted that Blackrock Neurotech aims to submit plans to make the products widely available in 2022.
“We are witnessing the start of a revolution in the diagnosis and treatment of neurological disorders and disabilities,” Solzbacher said. “Ten years from now, neural implants could be as common as pacemakers are today, offering patients a whole new world of options that restore their independence.